Boston Partners’s United Therapeutics UTHR Stock Holding History

Boston Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-4,300	Closed	-$582K	–	785
2017 Q1	$582K	Buy	+4,300	New	+$651K	﹤0.01%	725

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Boston Partners's UTHR Position: Q2 2017 in Review

Boston Partners sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 4,300 shares — an estimated $582K sold.

Boston Partners first reported a position in UTHR in Q1 2017 and held it in 1 quarter. The position peaked at $582K in Q1 2017. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

Boston Partners reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
Boston Partners sold 4,300 United Therapeutics shares in Q2 2017, an estimated $582K.
Boston Partners first reported a position in United Therapeutics in Q1 2017 and held it in 1 quarter.
Boston Partners's United Therapeutics position peaked at $582K in Q1 2017.
373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Boston Partners's 13F filing for Q2 2017, filed 2 Aug 2017.